Clinical trials: Intestine
Colorectal Neoplasms, Neoplasm Metastasis
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan…
- Trial name
- VELOUR (NCT00561470)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 221 sites in United States, Argentina and 26 more
- Volunteers
- 1,226 people
- Sponsor
- Sanofi
Colorectal Cancer
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or…
- Trial name
- CLAUDE (NCT05350501)
- Testing
- EO2040
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Enterome
Crohn's Disease
Efficacy and Safety of TD-1473 in Crohn's Disease
A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.
- Trial name
- DIONE (NCT03635112)
- Testing
- TD-1473
- Where
- 178 sites in United States, Australia and 20 more
- Volunteers
- 167 people
- Sponsor
- Theravance Biopharma
Malignant Bowel Obstruction
Palliative Management of Inoperable Malignant Bowel Obstruction
To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
- Trial name
- NCT04027348
- Testing
- Dexamethasone, Metoclopramide, Octreotide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Inflammatory Bowel Diseases
Chronotherapy in Inflammatory Bowel Disease
This study aims to determine if there is any difference in the efficacy of Inflammatory Bowel Disease (IBD) medication and disease outcomes when taken in the morning or in the evening.
- Trial name
- NCT04304950
- Testing
- Evening Group, Morning Group
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rush University Medical Center
Hypertriglyceridemia, Inflammation
Impacts of Lentils on Metabolism and Inflammation
The overall goal of this investigation is to determine gut microbiome dependent and independent impacts of pulse consumption on metabolic resilience and metabolic risk profiles for type 2 diabetes (T2D) and cardiovascular disease…
- Conditions
- Hypertriglyceridemia, Inflammation, Waist, Hypertriglyceridemic
- Trial name
- NCT04283448
- Testing
- Dietary Lentil, Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Montana State University
Colorectal Cancer
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer.
- Trial name
- NCT00796718
- Testing
- Standard radiotherapy, Capecitabine [Xeloda]
- Where
- 2 sites in Slovakia
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Celiac Disease
Desensitising Celiac Disease Patients With the Human Hookworm
We have established that the hookworm Necator americanus (Na) dramatically alters the local and systemic immune landscape of the infected human host.
- Trial name
- NaCeD (NCT01661933)
- Testing
- Necator americanus
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- The Prince Charles Hospital
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Colorectal Cancer
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed…
- Trial name
- NCT02295774
- Testing
- Methylene Blue MMX tablets
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Familial Adenomatous Polyposis
Curcumin in Treating Patients With Familial Adenomatous Polyposis
This randomized phase II trial studies curcumin in treating patients with familial adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal polyps or colorectal neoplasia.
- Trial name
- NCT00641147
- Testing
- Curcumin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Colitis, Ulcerative
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis.
- Trial name
- NCT04613518
- Testing
- BMS-986165
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Inflammatory Bowel Disease
A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease
The purpose of this study was to evaluate the impact of the co-morbidities profile on treatment response to biological therapy in inflammatory bowel disease (IBD) participants.
- Trial name
- NCT02861118
- Testing
- No Intervention
- Where
- 23 sites in Spain
- Volunteers
- 310 people
- Sponsor
- Takeda
Cancer of Head and Neck, Cancer of Cervix
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).
- Conditions
- Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
- Trial name
- NCT02865135
- Testing
- DPX-E7 vaccine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Crohn Disease
Loss of RESponse to Ustekinumab Treated by Dose Escalation
The aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W)…
- Trial name
- REScUE (NCT04245215)
- Testing
- Ustekinumab
- Where
- Belgium
- Volunteers
- 108 people
- Sponsor
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
- Trial name
- NCT01931150
- Testing
- Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
- Trial name
- NCT00203411
- Testing
- Capecitabine (Xeloda), Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Translational Oncology Research International
Metastatic Colorectal Cancer
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00252564
- Testing
- Bevacizumab, Oxaliplatin, Leucovorin
- Where
- 82 sites in United States
- Volunteers
- 247 people
- Sponsor
- US Oncology Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.